22nd Century Group, Inc.

   

XXII
Symbol Name Last Trade Price Change Change (%) Volume




Revenue 1 year Target Price 52 week Range Stock Exchange Last Trade Size

22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Breaking News Arrows

Breaking News

  • 22nd Century Enters CBD Space With $24M Investment In PanaceaDecember 5, 2019Investments are anticipated to total $24 million, in a combination of cash and 22nd Century stock. “Our objective is to build a leading, profitable business in the fast-growing, emerging, legal hemp/cannabis space, and Panacea is a rapidly-growing, vertically-integrated, consumer-facing business with a very strong management team," Cliff Fleet, President and CEO of 22nd Century Group said in a statement.
  • Shareholder Alert: Robbins LLP Reminds Investors 22nd Century Group, Inc. (XXII) Sued for Misleading ShareholdersDecember 3, 2019Shareholder rights law firm Robbins LLP reminds investors that purchasers of 22nd Century Group, Inc. filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 18, 2016 and July 31, 2019.
  • 22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.December 3, 2019Williamsville, NY, Dec. 03, 2019 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today the initial closing of an investment in Panacea Life Sciences, Inc. (Panacea), a rapidly-growing, vertically-integrated, consumer-facing company operating exclusively in the legal, hemp-derived, CBD product space. 22nd Century’s investments in Panacea over the next twelve to eighteen months are expected to total $24 million, in a combination of cash and 22nd Century stock in exchange for Panacea-issued debt and preferred equity.
  • Edited Transcript of XXII earnings conference call or presentation 8-Nov-19 2:00pm GMTNovember 27, 2019Q3 2019 22nd Century Group Inc Earnings Call
  • 22nd Century Group Comments on Delay of Reduced Nicotine Rule for CigarettesNovember 21, 2019Williamsville, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, responded today to the FDA’s recent removal of the Tobacco Product Standard for Nicotine Level of Certain Tobacco Products from the Trump administration’s ‘unified agenda.’  The much anticipated Notice of Proposed Rulemaking (NPRM) for the reduced nicotine product standard, which was expected in October, was listed as being “Withdrawn” as of October 23, 2019, on the White House Office of Information and Regulatory Affairs website. The unified agenda was updated with the new information on Wednesday, November 20, 2019, as part of a semiannual review.